Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis. [electronic resource]
Producer: 20180924Description: 85-89 p. digitalISSN:- 2185-2243
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bevacizumab -- administration & dosage
- Carboplatin -- administration & dosage
- Carcinoma, Ovarian Epithelial
- Disease-Free Survival
- Drug Resistance, Neoplasm
- Female
- Humans
- Middle Aged
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasms, Glandular and Epithelial -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Paclitaxel -- administration & dosage
- Propensity Score
- Retrospective Studies
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Observational Study
There are no comments on this title.
Log in to your account to post a comment.